Paris, France and Cambridge, Massachusetts - February 16, 2011 /PRNewswire/ - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Genzyme Corporation (NASDAQ: GENZ) announced today that they have entered ...

Pharmaceuticals-maker Sanofi-Synthelabo formally announced plans Monday to create the world’s third-largest pharmaceutical company after making a new, “friendly” bid for the Franco-German Aventis SA ...

SkillsFuture- and IBF-funded courses by Aventis equip Singaporeans with future-ready skills in AI, ESG, wellness, and digital transformation. Through SkillsFuture-funded training in areas such as AI, ...

PARIS, March 11 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has completed its acquisition of 100% of Chattem, Inc ...

PARIS, April 8, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has completed its acquisition of Genzyme Corporation, which is now a wholly-owned subsidiary ...

French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront of the ...

Where there are threats of serious or irreversible damage, lack of full scientific certainty shall not be used as a reason for postponing cost-effective measures to prevent environmental degradation. ...

Aventis Pharma has reported a sales turnover of Rs 345.70 crore and a net profit of Rs 40.10 crore for the quarter ended Mar '12 Aventis Pharma has recommended a final dividend of Rs 29 per share of ...

French drugmaker Sanofi-Aventis SA said Monday it plans to buy U.S. health-care company Chattem Inc., maker of over-the-counter mainstays like Gold Bond skin products, for $1.9 billion in cash. The ...

VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- Aventis Energy (“Aventis” or the “Company”) (CSE:AVE | FRA:C0O0 | OTC: VBAMF) is pleased to announce the appointment of Michael Mulberry, ...